TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05286216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effectiveness of education
Description: The education program will be prepared using power point presentations within the relevant scientific literature. The education program is planned to be given to each group as 1 session on 2 different days, between 09:30 and 13:00. Day 1 module 1; Module 2 will be shared on the 2nd day and all patients in the experimental group will participate in the education program. During and after the education, individuals will be provided with the opportunity to ask questions. In addition, after the education, the researcher's phone will be given and counseling will be provided by phone. The duration and subject of the telephone conversations will be recorded by the researcher.~In order to evaluate the training, all patients will be invited to the hospital on the day of the control at the end of 12 and 24 weeks, and evaluations will be made again with data collection tools.
Study: NCT06190431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning the use of an in-exsufflation device with the guidance of a physiotherapist
Description: Learning to use an in-exsufflation device with the guidance of a physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Learning the use of an in-exsufflation device with the guidance of a physiotherapist
Description: Learning to use an in-exsufflation device with the guidance of a physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using the coaching mode
Description: Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
Study: NCT04064918

Intervention type: OTHER
Group type: OTHER
Intervention: Netarsudil 0.02% QD
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
Study: NCT05651802

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
Study: NCT06321094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
Study: NCT05804357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
Study: NCT04507347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC041266
Description: TRC041266 sachet 1500 mg strengths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TRC041266 sachet 1500 mg matching placebo
Study: NCT05858359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPACT program
Description: During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home.
Study: NCT06121778

Intervention type: OTHER
Intervention: Home
Description: There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
Study: NCT01427816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05964309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine group
Description: after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sitting group
Description: after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
Study: NCT06257563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isle of TEND Intervention
Description: The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers.
Study: NCT05803122

Intervention type: OTHER
Intervention: Uniform Data Set (UDS) neuropsychological battery
Description: Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease

Intervention type: OTHER
Intervention: Uniform Data Set (UDS) neuropsychological battery
Description: Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
Study: NCT05534776

Intervention type: OTHER
Intervention: Investigator Global Assessments (IGAs)
Description: 5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.

Intervention type: OTHER
Intervention: Investigator Global Assessments (IGAs)
Description: 5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
Study: NCT04766996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided mindfulness exercises
Description: Guided Meditation twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered aromatherapy
Description: Self-administered aromatherapy every 6 hours and at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby aspirin
Description: Baby aspirin 81mg: Twice daily for 6 weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol/Acetaminophen
Description: Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5mg: Daily for three weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec
Description: Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren
Description: Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: Zofran 4 mg pre-operative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepcid
Description: Pepcid 20 mg pre-operative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reglan
Description: Reglan 10 mg pre-operative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Versed
Description: Versed 2 mg pre-operative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
Study: NCT05236244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention group
Description: Diaphragmatic Breathing Exercises
Study: NCT05282420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Ranibizumab
Description: intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Aflipercept
Description: intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflipercept
Study: NCT04088591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500Mg/Ml Inj
Description: Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose in Water
Description: 50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
Study: NCT05510284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doula-coordinated, midwife-delivered postpartum care
Description: A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
Study: NCT04687371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive vestibular exercise
Description: To assess effects of proprioceptive vestibular exercises training in patients with peripheral vestibular hypofunctions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard vestibular rehabilitation exercises
Description: To assess effects of standard vestibular rehabilitation exercises in patients with peripheral vestibular hypofunctions

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled
Description: First and last measurement will be taken. There will be no intervention. study will include 9 patients.
Study: NCT06526052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Online, coached mindfulness training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Remote meetings with a supportive coach
Study: NCT04766996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 10-125 mcg/kg/min intraoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancef
Description: Ancef 2-3 gm weight-based dosing intraoperative
Study: NCT05547308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D myoelectric prosthetic device
Description: All subjects will use the 3D Prosthetic device and complete a variety of quality of life questionnaires.
Study: NCT05825976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty ACids
Description: Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty ACids
Description: Intervention consists of two different doses of omega-3: high concentration (Intervention group 1) and low concentration (Intervention group 2).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Supplementation with extra virgin olive oil as a for of positive placebo control.
Study: NCT04064918

Intervention type: OTHER
Group type: OTHER
Intervention: Timolol maleate 0.5% BID
Description: This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
Study: NCT03905902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: activated autologous dendritic cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DCVAC/OvCa
Description: activated autologous dendritic cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa placebo
Description: placebo for activated autologous cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DCVAC/OvCa placebo
Description: placebo for activated autologous cells
Study: NCT05254327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.
Study: NCT05387668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet.
Study: NCT04969692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming to increase local skin (puncture site) temperature
Description: According to the group of participants, investigator applies the warmer to the hands and wrists of the participants, makes a local temperature of 40℃ gradually, and maintains it for about 10 minutes in warming group (which is divided in to warming-palpation (WP) and warming-US (WU) group).
Study: NCT06085313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAI
Description: Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPA
Description: Web App-based information and coaching/support program for cancer pain management
Study: NCT05629468

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: antibiotic

Intervention type: DRUG
Group type: OTHER
Intervention: Probiotic Formula
Description: probiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: probiotics

Intervention type: DRUG
Group type: OTHER
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide 4 % Topical Cream
Description: topical cream
Study: NCT05019534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib Oral Tablet [Zelboraf]
Description: Vemurafenib 960mg qd or 960mg bid (2 cohorts)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection [Erbitux]
Description: Cetuximab 500mg/m2 Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg Q2W
Study: NCT05894811

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: Nine blood samples were collected from subjects within 4 hours of oral glucose administration, 0 min before oral glucose administration, and 10, 20, 30, 60, 90, 120, 180, 240 min afterwards, and 4 mL of venous blood was collected at each time point for glucose, C-peptide and insulin concentrations.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Using MRI to quantify of fat content in the liver and pancreas of the subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Using MRI to quantify of fat content in the liver and pancreas of the subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Using MRI to quantify of fat content in the liver and pancreas of the subjects
Study: NCT06217003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Preoperative application of trilaciclib during perioperative chemotherapy
Study: NCT04766996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: Tranexamic Acid (TXA) 2 gm intraoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg intraoperative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
Study: NCT05504005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection
Description: Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
Study: NCT04766996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
Study: NCT04720300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MaaS app
Description: The MaaS App will be downloaded to students' smartphones and will provide real-time, multimodal trip planning to students on demand when they open the app.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No app
Description: students receive no app or housing information
Study: NCT05643534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 MG
Description: Participants will receive tenapanor 50 mg BID (total of 100 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor 25 mg bid
Description: Participants will receive tenapanor 25 mg BID (total of 50 mg daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive matching placebo
Study: NCT06284512

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonography, color fundus photography
Description: Patients will undergo routine diagnostic imaging (Sonography, color fundus photography)
Study: NCT05496829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Adherence Intervention
Description: The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Receipt of usual care from providers
Study: NCT06310330

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive echocardiographic follow-up
Description: Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified echocardiographic follow-up
Description: Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
Study: NCT05481567

Intervention type: OTHER
Intervention: Questionnaire
Description: A series of 14 questions about with the impact of periodontitis on quality of life.

Intervention type: OTHER
Intervention: Questionnaire
Description: A series of 14 questions about with the impact of periodontitis on quality of life.
Study: NCT04819555

Intervention type: GENETIC
Intervention: Blood
Description: a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
Study: NCT05044455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
Study: NCT05012189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir
Description: Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.